Preclinical Rationale and Clinical Translation for Marengo's Selective Dual T Cell Agonist, Invikafusp Alfa as a Novel IO Backbone in Combination with ADCs

Session details:

Preclinical mechanistic and efficacy data that established the rationale for advancing Marengo's novel immunotherapy–ADC combination into a Phase 1/1b clinical trial.